Bayer inks up with “small” Indian biotech for new approach at an old target

Curadev, the self-admittedly “small” Indian biotech, has racked up another big-name partnership.

Bayer has promised up to €250 million ($267 million) in biobucks for access to Curadev’s STING platform, the same one that Takeda jumped in on last May. The deal gives Bayer rights to treatments for a series of lung, cardiovascular and inflammatory diseases. Takeda had licensed the lead molecule from that platform, an antibody drug conjugate for immuno-oncology.